ASTRAZENECA UK LIMITED

Assessment

Entity identity is VERIFIED against the UK statutory registry. All mandatory identification attributes were retrieved and are internally consistent. The registered office in the evidence matches the address appearing in the FCA clone warning discussed in Section 6, which corroborates the identity of the entity being referenced in that open-source item.

Evidence

Not Retrieved

The following identity attributes were NOT FOUND in the supplied evidence and are material gaps:

• SIC code / stated nature of business. No registry-confirmed business activity was retrieved. The pharmaceutical characterisation implied by the open-source hits (CMS drug-price negotiation listing, patent litigation) is contextual inference from third-party sources, not registry data, and is not relied upon as verified.
• Previous names / former registered addresses. Not retrieved; relevant to name-variant screening completeness in Section 3.
• Accounts and confirmation-statement filing history and any filing-default markers. Not retrieved; see Section 8.
• Legal Entity Identifier (LEI). Not retrieved.

Risk Implication

The identification limb of MLR 2017 reg. 28(2) is satisfied for a body corporate: name, company number, registered office and legal form are established from an authoritative registry. The absence of a registry-confirmed business activity is a secondary but real gap — under a risk-based approach the firm cannot fully assess whether the customer's stated purpose and intended nature of the business relationship (reg. 28(9)) is consistent with its registered activity. Obtain the full Companies House profile including SIC codes and filing history.

Assessment

Control is partially established. Twelve officers are CONFIRMED from the Companies House officers register. Ownership, by contrast, terminates at a single declared corporate PSC with no upward chain, no percentage disclosure and no identified natural person. Under this report's evidence taxonomy there is no confirmed ultimate beneficial owner.

The 25% Threshold

Under the UK PSC regime (Companies Act 2006 Part 21A, as amended) and MLR 2017 reg. 5, a person with significant control is, in broad terms, one who holds more than 25% of shares or voting rights, holds the right to appoint or remove a majority of the board, or otherwise exercises significant influence or control. The PSC filing here identifies a corporate PSC. The evidence does not state which control condition is met, nor the percentage band. Consequently the 25% test cannot be evaluated against any natural person on the present record.

Registry-Confirmed Officers

Note on the officer list: appointment as a director is a fact of registry record. It carries no adverse implication whatsoever for any named individual. None of these individuals is linked by the evidence to any allegation, investigation or proceeding.

Declared Ownership

Missing and Why It Matters

1. 1.The PSC's own registration number was not retrieved. Without it, the corporate PSC cannot be reliably resolved to a specific registry record, and name-based matching risks selecting the wrong entity.
2. 2.The percentage / nature-of-control band was not retrieved. The specific PSC condition satisfied is unknown.
3. 3.The chain above Astrazeneca Intermediate Holdings Limited was not traced. No ultimate parent and no ultimate natural person is evidenced. The report does not assert any group parent, because none appears in the evidence.
4. 4.No nominee, trust or shareholder-agreement arrangements were tested.

Risk Implication

FATF Recommendation 24 and MLR 2017 reg. 28(4) require the firm to take reasonable measures to identify beneficial owners and to understand the ownership and control structure — reliance on the PSC register alone is expressly insufficient under reg. 28(4)(b)/(c). EU 5AMLD Article 30 embeds the same principle for in-scope EEA structures. The opacity here is structural rather than suspicious: a single declared corporate PSC in a low-transparency-risk jurisdiction is a common and unremarkable subsidiary pattern, which is why Transparency Risk scores only 8/100 in Section 11. It is nevertheless an unclosed gap. Obtain the corporate chain to ultimate natural persons, or documentary confirmation of listed-parent status if applicable, before final file sign-off. The unresolved identity of the ultimate controllers also constrains Section 3 (only the subject entity name was screened, not the full ownership chain) and Section 4 (no controller-level PEP screening was possible).

Assessment

Screen status: RUN — genuine nil return. Sanctions screening against OFAC, UK OFSI and UN lists executed and returned no findings (source ledger: OK_EMPTY). This is a meaningful clean result and is the principal reason the composite score sits in the medium rather than a higher band: the sanctions factor carries the largest applied weight (34.1%) and scores 3/100.

Evidence

Scope Limitations — Material

• Only the subject entity appears to have been screened. The evidence does not confirm that the twelve registry-confirmed officers in Section 2, or the declared corporate PSC (Astrazeneca Intermediate Holdings Limited), were separately screened. Under a risk-based approach, directors and beneficial owners should be screened in their own right.
• List coverage is limited to OFAC, UK OFSI and UN. EU consolidated list, Swiss SECO, Canadian and Australian regimes, and sectoral/ownership-derived (50% rule) exposure were not evidenced as screened.
• No name-variant or transliteration testing is evidenced. Former names were not retrieved (Section 1), so historical-name screening completeness cannot be confirmed.
• No adverse control-chain analysis. Because the ownership chain above the declared PSC is untraced (Section 2), indirect ownership by a designated person cannot be excluded by this screen.

Risk Implication

On the lists screened, the entity is not designated. That is a defensible finding for MLR 2017 reg. 33 purposes and for the firm's obligations under the Sanctions and Anti-Money Laundering Act 2018 and OFSI reporting duties. It is not a statement that no sanctions nexus exists anywhere in the group. Extend screening to officers, the declared PSC and the traced parent chain, and re-run on the quarterly cycle set in Section 12. Note that the Atchley litigation described in Sections 5 and 7 concerns alleged conduct in a context associated with counter-terrorism litigation in the United States; while no sanctions designation arises from it on this record, it is a reason to hold the sanctions screen at a higher frequency than routine.

Screen status: NOT RUN

Assessment

No PEP screening was performed. The source ledger records: 'No PEP screening provider configured [PEP] → SKIPPED'. Accordingly:

• No PEP status has been established or excluded for the subject entity, for any of the twelve registry-confirmed officers, or for any beneficial owner.
• No RCA (relative or close associate) analysis was performed.
• No HIO (head of international organisation) analysis was performed.
• No political position, jurisdiction of exposure or time period can be stated, because no screening data exists.

This report explicitly does not conclude that the entity or its officers are non-PEP. Role titles in the Companies House register ('director', 'secretary') are corporate roles and carry no PEP information; inferring non-PEP status from them would be methodologically invalid and is not done here.

Compliance Implication

Aggravating Context

The adverse-media and litigation evidence (Sections 5 and 7) references allegations of bribery and corrupt payments in the Atchley proceedings. Bribery allegations and PEP exposure are analytically adjacent risk categories: where corrupt-payment allegations exist, the identification of any politically exposed counterparties or controllers becomes materially more important, not less. The absence of a PEP screen is therefore a HIGH-severity gap on this particular file, not a routine one.

Required Next Step

Run PEP/RCA/HIO screening against:

1. 1.All twelve named officers listed in Section 2 (using full names and dates of birth obtained from the Companies House officer records).
2. 2.The declared corporate PSC, Astrazeneca Intermediate Holdings Limited, and every entity in the chain above it once traced.

No onboarding decision should be finalised until this screen is complete.

Assessment

Adverse media screening ran via Google Programmable Search only. Ten results were returned: 3 adverse, 1 positive, 6 neutral; adverse severity distribution critical 0, high 3, medium 0, low 0. Assessed on the substance rather than the automated classification, the three HIGH items reduce to one substantive matter (the Atchley proceedings, represented twice) plus one probable false positive (a CMS programme-participation listing). The resulting Adverse Media factor score of 66/100 (22.7% applied weight) should be read with that caveat.

Adverse Items — Full Detail

Attribution Discipline

The references to bribery and corruption are claims made by plaintiffs and characterisations recorded in court materials and reported by FindLaw and CourtListener. The evidence set contains no finding by any court or regulator that ASTRAZENECA UK LIMITED committed bribery or corruption. The following distinctions are held throughout this report:

• Allegation — present (civil pleadings in Atchley).
• Investigation — no evidence of any regulatory or criminal investigation of the entity.
• Charge — none evidenced.
• Conviction / adjudicated liability — none evidenced.

Coverage Limitations

• Single-provider search. No specialist adverse-media database (e.g. structured news-risk provider), no non-English-language search, and no defined look-back period were applied. The 'time span' of coverage cannot be stated because result dates are largely marked UNDATED.
• Ten results is a shallow corpus for an entity of this evident profile; absence of further adverse coverage is NOT FOUND, not NONE.
• The single 'positive' item and six 'neutral' items were not itemised in the evidence supplied and cannot be described.

Risk Implication

AML/CTF relevance is real but bounded. Allegations of corrupt payments, if ever established, would constitute predicate-offence conduct relevant to MLR 2017 and the Bribery Act 2010, and would materially change this assessment. As matters stand, the reputational exposure is that of a defendant in contested civil proceedings. The matter should be tracked to disposition, which is the principal driver of the quarterly monitoring frequency recommended in Section 12. This finding is directly connected to the litigation record in Section 7 and to the regulatory classification issue in Section 6.

Assessment

The Regulatory & Enforcement factor scores 77/100 (20.4% applied weight) — the highest single-factor score in the model. On analyst adjudication this score is not supported as an enforcement signal. Both adverse items in this domain were surfaced by generic web search and neither, on the face of the evidence, is an enforcement action against ASTRAZENECA UK LIMITED.

Evidence

The FCA Clone Warning — Correct Interpretation

The FCA publishes clone warnings to alert consumers that fraudsters are impersonating a firm. The snippet reproduces the genuine firm's details — name, Firm Reference Number 653398, and the Cambridge Biomedical Campus address that matches the Companies House registered office confirmed in Section 1. The correct reading is that the subject was the impersonated party, not the wrongdoer.

Caveat on FRN 653398: the FRN appears in a third-party-retrieved snippet. The FCA Financial Services Register was not independently queried in this assessment — it does not appear in the source ledger. Whether ASTRAZENECA UK LIMITED currently holds, or has ever held, FCA authorisation or registration under that FRN, and in what capacity, is UNVERIFIED. This should be resolved directly against the FCA Register, since regulated status materially affects the applicable CDD approach.

What Was Not Searched

No primary regulator database was queried. Specifically NOT RUN (and therefore incapable of supporting any clean conclusion):

• FCA Financial Services Register and FCA enforcement/final-notices database
• MHRA regulatory action records
• CMA / SFO / HMRC enforcement records
• US DOJ, SEC and FDA enforcement databases
• EU / EMA and other overseas regulators

Risk Implication

The 77/100 score is an artefact of keyword-driven classification, not of evidenced enforcement history. No regulator is shown by this evidence to have taken enforcement action against ASTRAZENECA UK LIMITED, and no penalty amount appears anywhere in the record. Equally, no primary enforcement database was checked, so a clean enforcement history has not been established — this is a NOT-SEARCHED position, not a nil-finding position. Two operational consequences follow: (1) run direct regulator checks before the score is treated as decision-grade; (2) apply anti-impersonation controls — verify firm identity, contacts and any payment instructions through independently sourced channels, given the documented clone activity.

Assessment

One adverse litigation item was returned out of ten results (1 adverse, 0 positive, 9 neutral; severity: high 1). Litigation scores 66/100 (11.4% applied weight). The evidence establishes that the entity is a named party in US federal proceedings that reached the US Supreme Court stage, and separately appears as a party in Canadian patent litigation. Court dockets were not searched directly — all litigation evidence derives from web search of publicly accessible court-adjacent websites.

Identified Proceedings

1. Atchley matter (United States)

2. AstraZeneca Canada Inc. v. Apotex Inc. (Canada)

3. Patent settlement referenced by a third party

Ono Pharmaceutical's FY2023 results reference a 'payment from the settlement of a patent-related lawsuit with AstraZeneca UK Limited' [https://www.ono-pharma.com/sites/default/files/en/ir/library/financialresults/presen/202405091en%3D0.pdf]. The settlement amount attributable to the subject is not disclosed; the figures on that slide relate to Ono's revenue, not the subject's. See Section 8.

Pattern Analysis

• Repeat litigation: the entity appears as a party in at least three distinct matters across three jurisdictions (US, Canada, and a settled patent dispute involving a Japanese counterparty). For a corporate of apparent scale in a patent-intensive sector this is an expected litigation profile rather than an anomaly.
• Class action: the Atchley matter involves multiple named plaintiffs ('et al.'). Whether it is certified as a class or aggregate action is NOT ESTABLISHED by the evidence.
• Insolvency proceedings: none identified. The registry status is active [Source: Companies House]. No insolvency register was searched, so this is NOT FOUND rather than confirmed nil.

Risk Implication

The material item is Atchley. Corrupt-payment allegations that survive to Supreme Court certiorari stage indicate a matter of substance and duration, and carry reputational and — if ever adjudicated adversely — predicate-offence significance under the Bribery Act 2010 and MLR 2017. No adverse adjudication against the entity is evidenced. Because the disposition is unknown and a 2026-dated appellate item exists, the matter is live for monitoring purposes. Obtain the primary docket. This finding is the same underlying event reported in Section 5 and partly drives the elevated composite in Section 11.

Assessment

No financial data for ASTRAZENECA UK LIMITED was obtained. The financial search returned ten results (1 adverse at MEDIUM severity, 9 neutral), of which the only itemised hit relates to a third party's financial reporting. Revenue, turnover, total assets, profitability, funding history and investor composition are all NOT FOUND.

Evidence

Source of Wealth / Source of Funds

Neither source of wealth nor source of funds can be assessed. On the available evidence the entity's funding structure is presumptively intra-group (a single declared corporate PSC), but this is inference, not evidence, and no intercompany funding, dividend or treasury arrangement has been documented.

Red-Flag Screening Against Standard Indicators

Risk Implication

This is an explicit due diligence deficiency. MLR 2017 reg. 28(9) requires the firm to obtain information on the purpose and intended nature of the business relationship, and ongoing monitoring under reg. 28(11) requires scrutiny of transactions for consistency with the firm's knowledge of the customer, its business and risk profile. Without any financial baseline, transaction monitoring for this relationship would have no calibration reference. Obtain the most recent statutory accounts from Companies House and, if the relationship is material, audited group financial statements and a documented expected-activity profile before limits are set.

Assessment

Jurisdiction Risk scores 35/100 (6.8% applied weight). The entity is incorporated in the United Kingdom and its registered office is in Cambridge, England [Source: Companies House]. No offshore incorporation, and no secrecy-jurisdiction nexus, appears in the registry evidence.

Evidence

Operating-Jurisdiction Exposure (from open sources only)

Open-source items place the entity's name in contact with the following jurisdictions. These are connections evidenced by third-party sources, not registry-confirmed operations:

Note: the Atchley snippets reference alleged bribery in a context the retrieved material does not geographically specify. This report does not attribute any particular high-risk operating country to the entity, because the evidence does not support it. If the primary docket identifies a high-risk jurisdiction nexus, the Jurisdiction factor must be re-scored.

Reference-Dataset Position

Screen status: NOT RUN for structured jurisdictional reference data.

No FATF, EU or Transparency International dataset appears in the source ledger. Specifically:

• FATF Grey List / Black List — not queried in this assessment; no publication date can be cited.
• EU High-Risk Third Countries list — not queried.
• Transparency International CPI — not queried; no CPI score can be stated for any jurisdiction in this report, and none is invented here.

The 35/100 jurisdiction score was applied by the scoring model; the underlying reference data supporting it was not surfaced in this run and cannot be independently reproduced from the evidence supplied.

Risk Implication

UK incorporation with a UK registered office is, in ordinary risk terms, a low-risk geographic baseline, and this is reflected in the modest weight and modest score. However, two qualifications apply: (1) the jurisdictional footprint of the ownership chain above the declared PSC is unknown (Section 2), so an unverified upstream jurisdiction cannot be excluded; (2) the entity's evidenced legal exposure is predominantly extraterritorial (US, Canada), which raises cross-border regulatory and reputational transmission risk even where the incorporation jurisdiction is benign. Confirm the incorporation jurisdiction of the declared PSC and of any traced parent.

Assessment

Screen status: NOT RUN for dedicated ESG data.

No ESG data source was consulted. The source ledger contains no ESG ratings provider, no modern-slavery statement register, no environmental regulator record and no data-breach or ICO enforcement lookup. All observations below derive from the general open-source searches already reported in Sections 5–7 and must not be read as an ESG assessment.

Position by ESG Domain

Framework Context

Under the UK Modern Slavery Act 2015 s.54, commercial organisations meeting the turnover threshold must publish an annual slavery and human trafficking statement. Because no turnover figure was retrieved (Section 8), it cannot be determined from this evidence whether the subject is in scope, and no statement was located. UN Global Compact participation status, TCFD-aligned climate disclosure and CSRD reporting obligations were likewise not tested.

Risk Implication

ESG and conduct risk is UNASSESSED, not low. This does not affect the composite score directly — ESG is not a weighted factor in this model (see Section 11) — but it is a material gap for any counterparty subject to internal responsible-business policies, procurement screening or investor ESG mandates. The one substantive conduct signal available, the Atchley bribery allegations, is a governance-domain matter and is tracked through Sections 5, 7 and 12 rather than here. If the relationship is ESG-sensitive, commission a dedicated ESG and modern-slavery screen before approval.

Composite Result

Composite score: 42/100 — MEDIUM. Coverage: PARTIAL. Confidence: MEDIUM.

Weights below are the applied (renormalised) weights, redistributed across the six domains that actually ran. PEP did not run and is therefore unweighted and unscored.

Scoring Table

Calculation

Composite Score = Σ(Factor Score × Applied Weight)

``` (3 × 0.341) = 1.023 (66 × 0.227) = 14.982 (77 × 0.204) = 15.708 (66 × 0.114) = 7.524 (35 × 0.068) = 2.380 (8 × 0.045) = 0.360

Σ = 41.977 → 42/100 (MEDIUM band) ```

PEP is excluded from both numerator and denominator; applied weights as supplied sum to 99.9% (rounding).

What Actually Drives the Score

1. 1.Regulatory & Enforcement (15.708 weighted points — the largest single contribution). Driven entirely by two items neither of which evidences enforcement against the subject. This is the weakest link in the composite and the highest-value target for re-scoring on primary evidence.
2. 2.Adverse Media (14.982). Driven by the Atchley matter (counted twice) and one probable false positive.
3. 3.Litigation (7.524). The Atchley matter again.

Concentration effect: approximately 22.5 weighted points — over half the composite — trace back to a single underlying litigation matter appearing in three domains, plus one misclassified programme-participation item. The composite therefore overstates the breadth of adverse exposure while accurately capturing that a substantive contested matter exists.

Suppression effect in the opposite direction: the clean sanctions result on the heaviest-weighted factor (34.1%) pulls the composite down by design. Had sanctions screening failed rather than returned nil, no defensible composite could have been produced at all.

Completeness Statement

This is a PARTIAL score and must not be presented as a complete risk picture. The PEP domain is entirely absent. Financial profile (Section 8) and ESG (Section 10) are unassessed and, by design, do not enter this model as weighted factors — their influence reaches the score only indirectly through Transparency Risk. Identity and beneficial ownership are likewise assessed narratively (Sections 1 and 2), not as weighted rows.

Recommendation

Standard CDD with Enhanced Monitoring. Enhanced Due Diligence is not required on the current evidence (EDD required: NO). Monitoring frequency: QUARTERLY. Next scheduled review: 25 November 2026 (report date 25 August 2026 plus one quarter).

Conditional hold: final onboarding or relationship-approval sign-off should not be given until the PEP screen (Section 4) is completed.

Rationale

Rejection is not supported by the evidence. Nothing in the record establishes an adjudicated finding of misconduct, a sanctions nexus, or deliberate opacity. Recommending termination on the basis of unrun screens would be disproportionate and inconsistent with the risk-based approach required by MLR 2017 reg. 18–19.

Outstanding Information Gaps

1. 1.PEP/RCA/HIO status of all twelve officers and of the beneficial ownership chain — not screened.
2. 2.Corporate chain from Astrazeneca Intermediate Holdings Limited to ultimate natural persons; PSC registration number; nature and percentage of control — not retrieved.
3. 3.Statutory accounts, turnover, assets, profitability — not retrieved.
4. 4.Current status and disposition of the Atchley proceedings — not retrieved.
5. 5.FCA Financial Services Register status and verification of FRN 653398 — not independently queried.
6. 6.Registry-confirmed SIC code / nature of business — not retrieved.
7. 7.Primary regulator enforcement databases (FCA, MHRA, SFO, CMA, US DOJ/SEC/FDA) — not queried.
8. 8.Dedicated ESG and modern-slavery screening — not performed.

Required Actions

1. 1.Run PEP/RCA screening on all twelve named officers and on the declared PSC and traced parent chain. Escalate to MLRO on any hit. (Blocking action — before approval.)
2. 2.Obtain the primary court record for Atchley v. AstraZeneca UK Limited (procedural posture, cause of action, any judgment) and re-score the Adverse Media, Regulatory and Litigation factors on primary evidence.
3. 3.Trace the ownership chain above Astrazeneca Intermediate Holdings Limited to ultimate natural persons or to documented listed-parent status; obtain the PSC's registration number and nature-of-control statement, satisfying MLR 2017 reg. 28(4).
4. 4.Verify FCA Register status directly, including FRN 653398, to establish whether the counterparty is a regulated firm and to confirm the correct CDD pathway.
5. 5.Obtain the latest filed statutory accounts from Companies House and document an expected transaction profile to calibrate monitoring.
6. 6.Formally adjudicate and downgrade the CMS item (Medicare drug price negotiation, 14 March 2025) as a search false positive, with the decision recorded on file.
7. 7.Apply anti-impersonation controls in light of the March 2022 FCA clone warning: verify counterparty contacts and all payment instructions through independently obtained channels; treat inbound changes to bank details as high-risk events.
8. 8.Extend sanctions screening to officers, the PSC and the traced chain, and add EU/SECO lists.

Trigger Events for Immediate Review (outside the quarterly cycle)

• Any adjudicated finding of bribery, corruption or fraud against the entity or any group company.
• Commencement of any criminal or regulatory investigation by any authority.
• Any sanctions or PEP hit on re-screening of the entity, officers or beneficial owners.
• Any change in PSC, control structure or registered status at Companies House.
• Publication of a further FCA clone or consumer warning referencing the entity.
• Insolvency, administration or strike-off action.
• Transaction activity materially inconsistent with the expected profile once established under Required Action 5.

Every URL behind a finding in this report. “Read in full” means the page itself was retrieved and classified on its whole text rather than on a search snippet; those carry a SHA-256 hash of exactly what was read, so the evidence can be shown to be unaltered later.

Complete Source Ledger

Date of assessment: 25 August 2026.

No source in this assessment returned a FAILED status. All gaps arise from sources that were SKIPPED or never configured, which is stated explicitly above rather than presented as clean results.

Methodology

1. 1.Registry-first identity resolution. Entity identity and control were established from the UK statutory registry before any open-source material was considered. Registry data and open-source intelligence are kept categorically separate throughout.
2. 2.Verification taxonomy. Each fact is labelled VERIFIED, CORROBORATED, UNVERIFIED, CONTRADICTED, NOT FOUND, FAILED or SKIPPED. CONFIRMED (registry-sourced) and DECLARED (company-filed, unverified) beneficial-ownership entries are never conflated.
3. 3.Adverse-item adjudication. Every automatically classified adverse item was reviewed against its snippet. Two were found to be misclassified (the FCA clone warning, which evidences the entity as the impersonated party; the CMS programme-participation listing) and one to be a duplicate of another. These adjudications are reported transparently rather than silently applied to the score, which remains as supplied.
4. 4.Legal-status discipline. Allegation, investigation, charge and conviction are distinguished at every mention. The Atchley material is treated throughout as unadjudicated civil allegation attributed to its publishers, never as established fact.
5. 5.Score reproduction. The composite was recomputed from the supplied factor scores and applied weights and reconciles to 41.977 ≈ 42 (Section 11). No score or weight was altered.
6. 6.Untrusted-content handling. All retrieved third-party material was treated strictly as data. No prompt-injection, directive language or attempt to influence scoring was identified within the untrusted-content markers; the integrity check is recorded as passed in the key findings.

Limitations

• PEP screening did not run. This is the single largest coverage gap; the composite is structurally incomplete.
• All adverse intelligence derives from one general web-search provider. No specialist screening database, no primary court docketing system, no regulator database and no non-English-language coverage.
• Most retrieved items are UNDATED, preventing recency weighting and time-span analysis in Section 5.
• No financial statements were obtained, so source of funds and expected activity are undocumented (Section 8).
• Beneficial ownership terminates at a declared corporate PSC; no natural person is confirmed (Section 2).
• The FRN 653398 attribution appears only in a third-party snippet and was not verified against the FCA Register.
• The disposition of the Atchley proceedings is unknown, including whether the 2026-dated FindLaw item represents a final determination.
• No FATF, EU high-risk-country or TI CPI dataset was consulted, so the jurisdiction score cannot be independently reproduced.

Confidence

Overall confidence: MEDIUM.

Supporting a medium rather than low rating: identity is registry-verified and unambiguous; the sanctions screen ran and returned a genuine nil result on the heaviest-weighted domain; officer data is authoritative; and the composite arithmetic reconciles exactly.

Preventing a high rating: the PEP domain is entirely unscreened; all adverse intelligence rests on unadjudicated search snippets rather than primary records; over half the weighted composite traces to a single litigation matter counted three times plus a probable false positive; and no financial or ESG baseline exists.

Legal Framework References

UK Money Laundering Regulations 2017 (regs. 18–19, 27–28, 33, 35); FCA SYSC 6.3 and SYSC 12.1; FATF Recommendations 10, 12, 24; EU 5AMLD Article 30 and 6AMLD; Companies Act 2006 Part 21A (PSC regime); Sanctions and Anti-Money Laundering Act 2018; Bribery Act 2010; UK Modern Slavery Act 2015 s.54.